EA201991667A1 - Экстренное лечение постоперационной тошноты и рвоты - Google Patents

Экстренное лечение постоперационной тошноты и рвоты

Info

Publication number
EA201991667A1
EA201991667A1 EA201991667A EA201991667A EA201991667A1 EA 201991667 A1 EA201991667 A1 EA 201991667A1 EA 201991667 A EA201991667 A EA 201991667A EA 201991667 A EA201991667 A EA 201991667A EA 201991667 A1 EA201991667 A1 EA 201991667A1
Authority
EA
Eurasian Patent Office
Prior art keywords
vomiting
postoperative nausea
emergency treatment
nausea
amisulpride
Prior art date
Application number
EA201991667A
Other languages
English (en)
Russian (ru)
Inventor
Джулиан Клайв Гилберт
Роберт Уильям Гриствуд
Габриель Фокс
Original Assignee
Экейше Фарма Лтд
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Экейше Фарма Лтд filed Critical Экейше Фарма Лтд
Publication of EA201991667A1 publication Critical patent/EA201991667A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EA201991667A 2017-02-10 2018-02-09 Экстренное лечение постоперационной тошноты и рвоты EA201991667A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1702250.0A GB201702250D0 (en) 2017-02-10 2017-02-10 Method
PCT/GB2018/050374 WO2018146490A1 (en) 2017-02-10 2018-02-09 Rescue treatment of post operative nausea and vomiting

Publications (1)

Publication Number Publication Date
EA201991667A1 true EA201991667A1 (ru) 2020-02-11

Family

ID=58462198

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201991667A EA201991667A1 (ru) 2017-02-10 2018-02-09 Экстренное лечение постоперационной тошноты и рвоты

Country Status (13)

Country Link
US (4) US11357753B2 (enExample)
EP (1) EP3579831A1 (enExample)
JP (2) JP7333269B2 (enExample)
KR (2) KR20190111993A (enExample)
CN (2) CN122351229A (enExample)
AU (2) AU2018218310B2 (enExample)
BR (1) BR112019016565A2 (enExample)
EA (1) EA201991667A1 (enExample)
GB (1) GB201702250D0 (enExample)
IL (2) IL268591B2 (enExample)
MX (1) MX388736B (enExample)
WO (1) WO2018146490A1 (enExample)
ZA (1) ZA201905212B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201702250D0 (en) 2017-02-10 2017-03-29 Acacia Pharma Ltd Method
IT201900013524A1 (it) * 2019-07-31 2021-01-31 Laboratori Baldacci Spa Nuove formulazioni di amisulpride
BR112023000167A2 (pt) * 2020-07-06 2023-01-31 Acacia Pharma Ltd Terapia de náusea e vômito pós-operatórios

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1004020A (en) 1964-04-24 1965-09-08 Standard Telephones Cables Ltd Improvements in or relating to the mounting of electrical components
FR2415099A1 (fr) 1978-01-20 1979-08-17 Ile De France Nouveaux derives de 4-amino-5-alkylsulfonyl ortho-anisamides, leurs procedes de preparation et leur application comme psychotropes
GB9305593D0 (en) 1993-03-18 1993-05-05 Smithkline Beecham Plc Pharmaceuticals
US6169094B1 (en) 1998-07-14 2001-01-02 Sanofi-Synthelabo Compositions of (S) (-)-amisulpride
DE10163421A1 (de) 2001-12-21 2003-07-31 Gruenenthal Gmbh Verwendung von (+)-(1S,2S)-3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)phenol als Antiemetikum
TWI355936B (en) 2003-02-18 2012-01-11 Helsinn Healthcare Sa Uses of palonosetron hydrochloride
DE102005013726A1 (de) 2005-03-22 2006-09-28 Grünenthal GmbH Transdermale therapeutische Systeme mit verbesserter Verträglichkeit
GB0506800D0 (en) 2005-04-04 2005-05-11 Merck Sharp & Dohme New uses
US8551986B2 (en) 2005-12-08 2013-10-08 The Mclean Hospital Corporation Treatment of sequelae of psychiatric disorders
JP5433236B2 (ja) 2006-01-27 2014-03-05 アプタリス ファーマテック,インコーポレイテッド 弱塩基性選択性セロトニン5−ht3遮断剤および有機酸を含む薬物送達系
WO2007096489A1 (fr) 2006-02-17 2007-08-30 Trimaran Limited Nouvelles compositions pharmaceutiques destinees a optimiser des traitements de substitution et elargir la pharmacopee au traitement global des addictions
US7825156B2 (en) 2007-02-02 2010-11-02 Copharms Method of treating bipolar depression with a benzamide derivative
EP2240022B1 (en) 2008-01-09 2016-12-28 Charleston Laboratories, Inc. Bilayered tablets comprising oxycodone and promethazine
WO2009126931A2 (en) 2008-04-11 2009-10-15 Xvasive, Inc. Combination therapy for bipolar disorder
US20110003005A1 (en) 2009-07-06 2011-01-06 Gopi Venkatesh Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions
PE20121483A1 (es) 2009-11-18 2012-12-02 Helsinn Healthcare Sa Composiciones para tratar nausea y vomito centralmente mediados
GB201004020D0 (en) 2010-03-11 2010-04-21 Acacia Pharma Ltd New therapeutic use
AU2011268073B2 (en) 2010-06-18 2015-07-16 Takeda Pharmaceutical Company Limited D2 antagonists, methods of synthesis and methods of use
JP2016532660A (ja) 2013-10-08 2016-10-20 イノファーマ インク アプレピタント経口液体製剤
GB201506116D0 (en) * 2015-04-10 2015-05-27 Acacia Pharma Ltd Kit and combination therapy for nausea and vomiting
GB201618425D0 (en) 2016-11-01 2016-12-14 Acacia Pharma Ltd method
GB201702250D0 (en) 2017-02-10 2017-03-29 Acacia Pharma Ltd Method

Also Published As

Publication number Publication date
US11357753B2 (en) 2022-06-14
BR112019016565A2 (pt) 2020-03-31
US12005042B2 (en) 2024-06-11
GB201702250D0 (en) 2017-03-29
IL268591B2 (en) 2023-04-01
JP2020506209A (ja) 2020-02-27
AU2018218310B2 (en) 2024-02-15
IL298486A (en) 2023-01-01
AU2024203155A1 (en) 2024-05-30
IL268591B (en) 2022-12-01
CN122351229A (zh) 2026-07-10
US20250367211A1 (en) 2025-12-04
JP7526244B2 (ja) 2024-07-31
KR20190111993A (ko) 2019-10-02
IL298486B2 (en) 2024-09-01
AU2018218310A1 (en) 2019-08-22
IL268591A (en) 2019-09-26
MX388736B (es) 2025-03-20
AU2024203155B2 (en) 2025-03-13
US20230100786A1 (en) 2023-03-30
CN110603036A (zh) 2019-12-20
ZA201905212B (en) 2023-12-20
US20200038369A1 (en) 2020-02-06
WO2018146490A1 (en) 2018-08-16
NZ756051A (en) 2024-04-26
JP7333269B2 (ja) 2023-08-24
US20240285579A1 (en) 2024-08-29
JP2023027213A (ja) 2023-03-01
EP3579831A1 (en) 2019-12-18
IL298486B1 (en) 2024-05-01
KR20240001288A (ko) 2024-01-03
NZ796242A (en) 2026-01-30
CA3052535A1 (en) 2018-08-16
US12329740B2 (en) 2025-06-17

Similar Documents

Publication Publication Date Title
EA201290833A1 (ru) Применение амисульприда в качестве противорвотного средства
MX2021002321A (es) Nuevos metodos.
IL268960A (en) 7,6,5,4-Tetrahydroisoxazazole (4,5-c) Pyridin-3-ol (thip) for use in the treatment of broken x syndrome
WO2015054619A3 (en) Use of a pcsk9 inhibitor to treat hyperlipidemia
MX384403B (es) Terapia de combinación para el tratamiento del cáncer.
WO2016133903A3 (en) Combination therapy for cancer treatment
MX390627B (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
WO2015123423A3 (en) Methods for treating patients with hypercholesterolemia that is not adequately controlled by moderate-dose statin therapy
EP4353317A3 (en) Ret inhibitor for use in treating cancer having a ret alteration
MX2019015212A (es) Compuestos para el tratamiento del sarcoma.
WO2017121646A8 (en) 3-(carboxyethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
EA202091112A1 (ru) Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение
EA201501164A1 (ru) Твердая фармацевтическая лекарственная форма
ZA201905212B (en) Rescue treatment of post operative nausea and vomiting
AU2017394032A8 (en) Use of paeoniflorin-6'-o-benzenesulfonate in treatment of sjögren's syndrome
EA202190317A1 (ru) Лекарственный препарат для наружного применения
EA201990995A1 (ru) Терапия постоперационной рвоты амисульпридом
EA202091062A1 (ru) Карбоксилхитозан
PH12020500606A1 (en) Use of functionalized calcium carbonate as active ingredient
UA117833U (uk) Спосіб лікування синдрому післяопераційної нудоти та блювання у пацієнтів після лапароскопічної холецистектомії
EA202090803A1 (ru) Фармацевтическая композиция адапалена и миноциклина для наружного применения
UA126148U (uk) Спосіб лікування періімплантного мукозиту
MX2021004997A (es) Tratamiento y prevencion de la eyaculacion precoz (ep).
CY1124264T1 (el) Απο toy στοματος θεραπευτικος παραγοντας του θυρεοειδους
EA201692163A1 (ru) Лекарственное средство для лечения пациентов с тиннитусом